Nyxoah (NASDAQ:NYXH – Get Free Report) and KORU Medical Systems (NASDAQ:KRMD – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.
Institutional & Insider Ownership
58.6% of KORU Medical Systems shares are owned by institutional investors. 17.1% of Nyxoah shares are owned by company insiders. Comparatively, 20.6% of KORU Medical Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Nyxoah and KORU Medical Systems’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nyxoah | -1,457.97% | -101.99% | -66.74% |
| KORU Medical Systems | -9.49% | -22.43% | -13.86% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nyxoah | $4.89 million | 26.05 | -$64.10 million | ($2.49) | -1.50 |
| KORU Medical Systems | $33.65 million | 6.26 | -$6.07 million | ($0.08) | -56.88 |
KORU Medical Systems has higher revenue and earnings than Nyxoah. KORU Medical Systems is trading at a lower price-to-earnings ratio than Nyxoah, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Nyxoah has a beta of 1.56, meaning that its share price is 56% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Nyxoah and KORU Medical Systems, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nyxoah | 1 | 0 | 3 | 1 | 2.80 |
| KORU Medical Systems | 1 | 1 | 3 | 1 | 2.67 |
Nyxoah currently has a consensus price target of $11.67, indicating a potential upside of 211.94%. KORU Medical Systems has a consensus price target of $6.13, indicating a potential upside of 34.62%. Given Nyxoah’s stronger consensus rating and higher possible upside, equities analysts plainly believe Nyxoah is more favorable than KORU Medical Systems.
Summary
KORU Medical Systems beats Nyxoah on 8 of the 13 factors compared between the two stocks.
About Nyxoah
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
About KORU Medical Systems
KORU Medical Systems, Inc. develops and manufactures medical devices and supplies in the United States and internationally. It offers the freedom infusion systems to deliver life-saving therapies to patients with chronic illnesses, such as primary immunodeficiency diseases, chronic inflammatory demyelinating polyneuropathy, and paroxysmal nocturnal hemoglobinuria. Its products include the FREEDOM60 syringe infusion system, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing products. The company was incorporated in 1980 and is based in Mahwah, New Jersey.
Receive News & Ratings for Nyxoah Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nyxoah and related companies with MarketBeat.com's FREE daily email newsletter.
